Next-generation AAV vectors for liver-directed gene therapy

Informazioni relative al progetto

AAVolution

ID dell’accordo di sovvenzione: 101071041

DOI

10.3030/101071041

Data della firma CE 11 Luglio 2022

Data di avvio 1 Ottobre 2022

Data di completamento 30 Settembre 2027

Finanziato da

• The European Innovation Council (EIC)

Costo totale

€ 4 500 000,00

Contributo UE

€ 4 500 000,00

Coordinato da

FONDAZIONE TELETHON ETS
Italy

Periodic Reporting for period 1 - AAVolution (Next-generation AAV vectors for liver-directed gene therapy)

Periodo di rendicontazione: 2022-10-01 al 2023-09-30

Sintesi del contesto e degli obiettivi generali del progetto

Over the past 20 years, scientists have made significant progress in a special kind of treatment for rare genetic diseases called liver-directed gene therapy, where viral-based carriers (AAVs) are used to deliver therapeutic genes to the liver. While this treatment has shown success in clinical trials, many patients still can't access it. The challenges include the temporary nature of the treatment in growing livers (newborns and children), potential side effects, and pre-existing immunity in some individuals. To tackle these issues, the AAVolution consortium has come together with the ambitious goal of developing new tools to enhance liver gene therapy. The strategy includes finding better tools for gene editing, creating self-replicating AAVs to make the treatment last longer, and designing safer synthetic AAVs. The ultimate aim is to significantly expand the toolkit for liver gene therapy, making it safer and more effective, thus helping patients who are currently excluded from these treatments due to immune issues, liver problems, or being too young. The project also envisions going beyond rare diseases and making this treatment available for a broader range of disease conditions.
Overall, the AAVolution team is focused on making liver gene therapy better and accessible to more people, potentially changing lives and opening up new possibilities in medicine.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

In the first project report, the AAVolution team achieved significant advancements in improving AAV vectors for liver gene therapy. As for the approach of gene editing and long-term effects (WP1), we found a promising Cas9 variant to be integrated into AAV vectors, which is effective for gene editing and is currently being tested in living organisms. We also explored ways to make the therapy last longer by investigating units that can autonomously replicate and maintain gene expression.
In addition, regarding the studies on AAV capsids (the carrier of therapeutic genes) (WP2), we created diverse libraries of AAV capsids to find the best ones for effective treatment. We used advanced techniques, including DNA shuffling and rational design, resulting in over 3000 variants. These variants underwent rigorous checks to ensure their quality.
In addressing pre-existing immune response challenges (WP3), we also generated important results. Through innovative approaches, we discovered 48 new Ide molecules, which hold promise in reducing immune responses to the therapy, and developed a machine learning flexible pipeline for designing more Ide. This is crucial for reducing immune responses against AAV therapy.
Overall, the AAVolution team is working to improve liver gene therapy better by using more effective gene-editing tools, exploring ways to make the therapy last longer, and creating diverse libraries of carriers for therapeutic genes. Additionally, the project is also addressing challenges related to the body's immune response to the therapy. These advancements bring hope for more effective and accessible gene therapies in the future.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

In the first project report, the AAVolution Project Management Team successfully coordinated various aspects, from organizing key meetings to communicating with the EU officers. We particularly emphasized managing intellectual property and devised a plan to safeguard AAVolution’s innovations.
In the strategic planning and regulatory engagement aspects, we submitted a comprehensive Cell and Gene Therapy (CGT) Strategic Plan, outlining objectives and collaborations with other projects. We also actively engaged with regulatory authorities through participation in an EMA webinar and maintained continuous interaction with private investors, showcasing their project in the EIC CGT Symposium.